Skip to content

Trial · Interventional

TerminatedPhase 3Results postedRegistry data

Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)

Overview

Status
Terminated
Phase
Phase 3
Enrollment
1,030 participants (actual)
Sponsor
Nordic Bioscience A/S · Industry
Design
Randomized · Double masking
Countries
10 countries

United States, Belgium, Canada, Czechia, Denmark, Hong Kong, Poland, Romania, Spain, United Kingdom

Start
Jun 2008
Primary completion
May 2011
Completion
Jun 2011
First posted
25 Jun 2008 (estimated)
Last update posted
24 Apr 2019
Conditions
Osteoarthritis

Timeline

1 trial · 1 stopped early · 1 with posted results

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20082009201020112012
  1. Ph 3

    Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)

    NCT00704847

    Jun 2008 to Jun 2011

    Terminated

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The purpose of this phase III study is to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Patients with Osteoarthritis of the Knee

Interventions

  • Oral Salmon CalcitoninDrug
  • Oral Salmon Calcitonin (Placebo)Drug

Arms2

  • Active comparator

    1

    SMC021 Oral Calcitonin

  • Placebo comparator

    2

    SMC021 Placebo

Primary outcomes2

Outcomes the sponsor listed as primary.

  1. Joint Space Width (JSW) in the Medial Tibia-femoral Knee Joint in the Signal Knee Measured by X-ray Change From Baseline Over 24 Months

    Time frame · Change from baseline to 24 months

    Registry description

    The signal knee was chosen prior to randomization based on which knee met the inclusion and exclusion criteria. The JSW is the space measured in mm between the 2 bones in the knee joint and this is assessed by x-ray. The JSW decreases with disease progression. The lower limit for participation in the trial were 2 mm JSW. There were no upper limit as long as inclusion and exclusion criteria were met. The outcome was measured as a change in JSW from baseline to month 24.

  2. Pain Subscore Change From Baseline Over 24 Months as Assessed by Western Ontario and McMaster Universities Arthritis (WOMAC) Index

    Time frame · Change from baseline to 24 months

    Registry description

    WOMAC is a self-administered set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee. The subject marks on a scale (1-100) the pain associated with performing each daily activity listed in the questionnaire. 0 is no pain (best), 100 is extreme pain (Worst). The total pain sub score for the questions are then calculated. Total possible minimum sub score is 0, maximum is 500. The final outcome is the absolute change from baseline to 24 months. If the outcome is less that 0 there is improvement (less pain).

Secondary outcomes(6)
  1. Bone & Cartilage Metabolism Biochemical Marker Change (Percentage).

    Time frame · From baseline to 24 months

    Registry description

    The central laboratory analyzed serum CTX-I (S-Crosslaps, Elecsys) and osteocalcin as well as urine CTX I/creatinine and CTX-II/creatinine. These biomarkers were analysed in order to assess the cartilage and bone turonver ratio to baseline at month 24.

  2. Knee Disease Progression Assessed by MRI

    Time frame · From baseline to month 12 and month 24

    Registry description

    Knee cartilage volume and thickness was assessed by MRI in patients from the sites in Ballerup, Denmark, the Czech Republic, and Romania using a quality controlled low-field 0.18T C-Span scanner from Esaote dedicated to the imaging of extremities. The same solenoid coil was used for all patients at a given site.

  3. Questionnaire to Assess Function and Physical Activity

    Time frame · From baseline to months 1, 6, 12 and 24

    Registry description

    Function and physical activity were assessed by assessed by WOMAC function sub-score in the signal knee. The criteria for assessment of the functional classification according to the American Rheumatism Association (ARA) were as follows (Hochberg et al 1992): I. Completely able to perform usual activities of daily living (self-care, vocational and avocational) II. Able to perform usual self-care and vocational activities, but limited in avocational activities. III. Able to perform usual self-care activities, but limited in vocational and avocational activities. IV. Limited ability to perform usual self-care activities, vocational and avocational activities. Self-care activities included dressing, feeding, bathing, grooming, and toileting. Avocational (recreational and/or leisure) and vocational (work, school, homemaking) activities were patient-desired and age- and sex-specific.

  4. Questionnaire to Assess Stiffness in the Signal Knee.

    Time frame · Baseline to month 24

    Registry description

    WOMAC's stiffness subscore was used to assess the stiffness in the signal knee. WOMAC is a self-administered set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee. The subject marks on a scale (1-100) the degree of joint stiffness for when performing each daily function listed in the questionnaire. 0 is no stiffness (best), 100 is extreme stiffness (worst). The total function sub score for the questions are then calculated. Total possible minimum sub score is 0, maximum is 200. The final outcome is the absolute change from baseline to 24 months. If the outcome is less that 0 there is improvement (less stiffness). Patients were instructed not to take analgesics for 3 days prior to the WOMAC test.

  5. Questionnaire to Assess Health-related Quality of Life

    Time frame · From baseline to month 24

    Registry description

    Health-related quality of life was assessed by the EQ-5D questionnaire, which is a patient questionnaire for measure of health, developed by the EuroQol Group.The EQ-5D questionnaire was administered to patients in order to measure change in health-related quality of life (HRQoL) over 2 years. The subjects marks on a VAS scale from 0 to 100 the number that best describes their health today (0 is worst imaginable health state and 100 is best imaginable health state). The change from baseline in the EQ-5D VAS was calculated.

  6. Questionnaire to Assess Pain

    Time frame · Baseline, month 1, month 6, month 12, month 24

    Registry description

    Pain was assessed by the WOMAC subscore in the signal knee by visit. Patients assessed their current pain level using a 100 mm visual analogue scales (VAS) by placing an X on the line that best describes his/her pain, where 0 equaled "No Pain" and 100 equaled "Worst Pain Imaginable". Patients were instructed not to take analgesics for 3 days prior to the VAS.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeMean· Change from baseline to 24 months

Joint Space Width (JSW) in the Medial Tibia-femoral Knee Joint in the Signal Knee Measured by X-ray Change From Baseline Over 24 Months

GroupValue (mm)Spread
SMC021 Oral Calcitonin-0.320.693
SMC021 Placebo-0.400.768
Primary outcomeMean· Change from baseline to 24 months

Pain Subscore Change From Baseline Over 24 Months as Assessed by Western Ontario and McMaster Universities Arthritis (WOMAC) Index

GroupValue (Units on a scale)Spread
SMC021 Oral Calcitonin-80.6112.22
SMC021 Placebo-87.9116.25
Secondary and other outcome results(6)
Secondary outcomeMean· From baseline to 24 months

Bone & Cartilage Metabolism Biochemical Marker Change (Percentage).

GroupValue (percentage of change)Spread
SMC021 Oral Calcitonin50.683.74
SMC021 Placebo40.645.52
Secondary outcomeMean· From baseline to month 12 and month 24

Knee Disease Progression Assessed by MRI

GroupValue (percentage of change)Spread
SMC021 Oral Calcitonin3.49.11
SMC021 Placebo3.013.16
Secondary outcomeMean· From baseline to months 1, 6, 12 and 24

Questionnaire to Assess Function and Physical Activity

GroupValue (percentage of change)Spread
SMC021 Oral Calcitonin-4.844.89
SMC021 Placebo-1.9131.20
Secondary outcomeMean· Baseline to month 24

Questionnaire to Assess Stiffness in the Signal Knee.

GroupValue (percentage of change)Spread
SMC021 Oral Calcitonin-26.190.88
SMC021 Placebo-20.3179.22
Secondary outcomeMean· From baseline to month 24

Questionnaire to Assess Health-related Quality of Life

GroupValue (percentage of change)Spread
SMC021 Oral Calcitonin13.7038.763
SMC021 Placebo11.8240.645
Secondary outcomeMean· Baseline, month 1, month 6, month 12, month 24

Questionnaire to Assess Pain

GroupValue (percentage of change)Spread
SMC021 Oral Calcitonin-6.749.50
SMC021 Placebo-9.145.26

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
GroupDeathsSerious eventsOther events
SMC021 Oral Calcitonin0.8 mg SMC021 Oral Calcitonin twice daily–77 / 520474 / 520
SMC021 Placebo1 SMC021 Placebo tablet twice daily–80 / 508459 / 508

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies2

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2015

3 results

Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials.

Karsdal et al. 2015Osteoarthritis and cartilagecited by 109

PMID 25582279DOI 10.1016/j.joca.2014.12.019PUB-25582279

Full text at the publisher3 results

More studies

1 study on this page

PubMed tag: none · 2026

Weight loss ameliorates symptoms of osteoarthritis and is correlated with alterations in soluble bone and cartilage markers: an analysis of patient-reported outcomes and biomarkers.

Bay-Jensen et al. 2026BMC rheumatology

PMID 41764561PMC13059256DOI 10.1186/s41927-026-00628-wPUB-41764561

Free to read · publisher termsCC BY-NC-ND
Read at source

Other registry references

References listed at the registry that are not in PepBank. They link to PubMed.

  • DerivedBihlet AR, Bjerre-Bastos JJ, Andersen JR, Byrjalsen I, Karsdal MA, Bay-Jensen AC. Clinical and biochemical factors associated with risk of total joint replacement and radiographic progression in osteoarthritis: Data from two phase III clinical trials. Semin Arthritis Rheum. 2020 Dec;50(6):1374-1381. doi: 10.1016/j.semarthrit.2020.03.002. Epub 2020 Mar 15. PMID 32249039
  • DerivedBihlet AR, Byrjalsen I, Bay-Jensen AC, Andersen JR, Christiansen C, Riis BJ, Karsdal MA. Associations between biomarkers of bone and cartilage turnover, gender, pain categories and radiographic severity in knee osteoarthritis. Arthritis Res Ther. 2019 Sep 3;21(1):203. doi: 10.1186/s13075-019-1987-7. PMID 31481084
  • DerivedBihlet AR, Byrjalsen I, Bay-Jensen AC, Andersen JR, Christiansen C, Riis BJ, Valter I, Karsdal MA, Hochberg MC. Identification of pain categories associated with change in pain in patients receiving placebo: data from two phase 3 randomized clinical trials in symptomatic knee osteoarthritis. BMC Musculoskelet Disord. 2018 Jan 17;19(1):17. doi: 10.1186/s12891-018-1938-5. PMID 29343266
  • DerivedHenriksen K, Bay-Jensen AC, Christiansen C, Karsdal MA. Oral salmon calcitonin--pharmacology in osteoporosis. Expert Opin Biol Ther. 2010 Nov;10(11):1617-29. doi: 10.1517/14712598.2010.526104. Epub 2010 Oct 11. PMID 20932224

Eligibility

Who could join, as posted.

Sex
All
Age
from 51 Years up to 80 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Medical history and symptoms of knee osteoarthritis Exclusion Criteria: * Any other disease or medication affecting the bone or cartilage. * Any clinical signs or laboratory evidence diseases, which in the Investigator's opinion would preclude the participant from adhering to the Protocol or completing the trial. Other protocol defined inclusion/exclusion criteria may apply

PepBank is a research reference. Talk to a doctor before you use any peptide.